secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bolt Biotherapeutics, Inc. (BOLT)
CIK:        0001641281
Form:       8-K
Filed at:   2025-03-24T23:59:59+00:00
Accession:  0000950170-25-043869
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bolt Biotherapeutics Q4 2024 loss from ops $16.9M; cash $70.2M; BDC-4182 starts trial Q2 2025
--------------------------------------------------------------------------------

- Q4 2024 loss from operations $16.9M vs $19.8M in Q4 2023; full-year loss $73.0M vs $76.2M.
- Collaboration revenue Q4 $7.7M (up from $2.1M Q4 2023); full year $7.7M (down from $7.9M).
- Cash $70.2M expected to fund key milestones and operations through mid-2026.
- BDC-4182 on track to start Phase 1 trial in gastric cancer in Q2 2025.
- BDC-3042 Phase 1 fully enrolled at highest dose; no DLTs; data update expected Q2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641281/000095017025043869/0000950170-25-043869-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641281/000095017025043869/bolt-20250324.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-043869

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer